Ligand Pharmaceuticals Incorporated (LGND)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	3,885	10,164	6,899	-2,475	8,742	-7,999	-6,318	-2,895	-23,708	5,781	19,928	64,227	75,550	77,370	65,411	26,772	25,845	4,456	-4,449	-15,679
Revenue (ttm)	US$ in thousands	167,133	152,422	133,478	118,313	131,314	153,595	186,815	217,868	219,582	241,673	240,420	267,676	277,133	274,650	251,663	208,408	186,419	143,432	126,392	109,959
Operating profit margin		2.32%	6.67%	5.17%	-2.09%	6.66%	-5.21%	-3.38%	-1.33%	-10.80%	2.39%	8.29%	23.99%	27.26%	28.17%	25.99%	12.85%	13.86%	3.11%	-3.52%	-14.26%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $3,885K ÷ $167,133K
= 2.32%

Ligand Pharmaceuticals Incorporated has displayed fluctuations in its operating profit margin over the specified period, ranging from negative figures to positive percentages. The trend indicates that there have been both periods of profitability and losses in the company's operations.

The operating profit margin improved significantly from negative values in early 2020 to peak at around 28% in September 2021. This surge was followed by a gradual decline in the margin, dropping to around 2% by September 2022. Subsequently, the operating profit margin experienced further volatility, with oscillations around the 0% mark and occasional positive values.

In summary, Ligand Pharmaceuticals Incorporated's operating profit margin has shown varying levels of profitability throughout the period under consideration, reflecting the company's ability to generate earnings from its core operations.